Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT03715829) tested different doses of an investigational medicine called PF-06651600 (also known as ritlecitinib) in people with non-segmental vitiligo — a skin condition where patches of skin lose their colour. The main dose-ranging phase enrolled 364 participants across five different dose groups and a placebo group (a dummy treatment with no active ingredient). A separate extension phase then followed, involving up to 293 additional participants across different treatment combinations. The trial's main goal was to measure changes in the amount of facial skin affected by vitiligo using a scoring system called the Facial Vitiligo Area Scoring Index (F-VASI) — a scale where a lower score means less affected skin. The reported data shows that, after 24 weeks, the facial vitiligo scores (F-VASI) changed by the following amounts compared to where participants started: the highest-dose groups (200 mg starting dose and 100 mg starting dose, both stepping down to 50 mg daily) each showed an average reduction of about 21%, the 50 mg daily group showed roughly 18.5% reduction, the 30 mg daily group around 14.6%, and the 10 mg daily group about 3%. The placebo group's score increased by about 2%, meaning on average their facial patches did not reduce. For a secondary measure looking at what share of participants achieved at least a 75% improvement in their facial score, the reported rates were: 12.1% in the highest-dose group, 8.5% and 7.7% in the next two dose groups, 2.7% and 2.3% in the lower-dose groups, and 0% in the placebo group. For whole-body vitiligo scores (T-VASI), the reported percentage changes at 24 weeks were small across all groups, ranging from roughly −2% to −5% in the active-dose groups and −1.4% in the placebo group, with no clear pattern separating the dose groups from placebo on this measure. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 42081176) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Vitiligo Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 65 years old (inclusive) at the time you agree to take part
- You have been diagnosed with moderate to severe active non-segmental vitiligo (a type of vitiligo that appears in patches on both sides of the body)
Who may not be able to join:
- You have a history of HIV or test positive for HIV at the screening appointment
- You are currently infected with hepatitis B or hepatitis C
- You have evidence of an active, latent (hidden/inactive), or not fully treated tuberculosis (TB) infection
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
7 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percent Change From Baseline in Central Read Facial-Vitiligo Area Scoring Index (F-VASI) at Week 24 - Dose Ranging (DR) Period; Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) up to Week 24 - DR Period; Number of Participants With the TEAEs of Anaemia, Neutropenia, Thrombocytopenia and Lymphopenia - DR Period; Number of Participants With Clinically Meaningful Changes From Baseline in Lipid Profile up to Week 24 - DR Period; Number of Participants With Liver Function Test Values Meeting the Protocol-Specified Discontinuation Criteria - DR...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.